May 22 (Reuters) - The U.S. Food and Drug
Administration's (FDA) staff on Wednesday pointed to "notable
imbalance" in incidence of low blood sugar in patients with type
1 diabetes treated with Danish drugmaker Novo Nordisk's
long-acting weekly insulin.
A panel of independent FDA advisers will meet on Friday to
review and discuss the safety and effectiveness of Novo's
insulin, icodec - an under-the-skin injection.